



# Green Chemistry

## Unlocking the photobiological conversion of CO<sub>2</sub> to (*R*)-3-hydroxybutyrate in cyanobacteria

Journal:	<i>Green Chemistry</i>
Manuscript ID	GC-ART-04-2018-001208.R1
Article Type:	Paper
Date Submitted by the Author:	08-Jun-2018
Complete List of Authors:	Wang, Bo; Arizona State University; National Renewable Energy Laboratory, Biosciences Center Xiong, Wei; National Renewable Energy Laboratory, Biosciences Center Yu, Jianping; DOE National Renewable Energy Laboratory, Maness, Pinching; NREL, Meldrum, Deirdre; Arizona State University, Biodesign Institute, Center for Biosignatures Discovery Automation

SCHOLARONE™  
Manuscripts

1 **Unlocking the photobiological conversion of CO<sub>2</sub> to (R)-3-**  
2 **hydroxybutyrate in cyanobacteria**

3 Bo Wang <sup>1,2,‡,\*</sup>, Wei Xiong <sup>2,‡</sup>, Jianping Yu <sup>2</sup>, Pin-Ching Maness <sup>2</sup>, Deirdre R. Meldrum <sup>1,\*</sup>

4 <sup>1</sup> *Center for Biosignatures Discovery Automation, The Biodesign Institute, Arizona State University,*  
5 *Tempe, AZ 85287-6501, USA.*

6 <sup>2</sup> *Biosciences Center, National Renewable Energy Laboratory, 15013 Denver West Parkway, Golden, CO*  
7 *80401, USA.*

8 <sup>‡</sup> Co-first authors.

9 \* Corresponding authors: [bo.wang@nrel.gov](mailto:bo.wang@nrel.gov) (B. Wang); [deirdre.meldrum@asu.edu](mailto:deirdre.meldrum@asu.edu) (D.R. Meldrum)

10

11

12

13

14

15

## 16 **Abstract**

17 Escalating concerns about CO<sub>2</sub> emission from fossil fuels utilization and environmental pollution  
18 from fossil-derived plastic waste call for the sustainable production and utilization of renewable  
19 biodegradable plastic materials. Polyhydroxyalkanoates (PHAs) are biodegradable and  
20 biocompatible thermoplastics with thermal and mechanical properties comparable to  
21 conventional plastics; thus, they are promising materials to mitigate environmental pollution.  
22 (*R*)-3-Hydroxybutyrate (3HB), which is the most common building-block for PHAs, has the  
23 potential to be utilized in various medical applications and can also serve as a precursor to a  
24 variety of value-added stereospecific chemicals. In addition, it can be produced by  
25 microorganisms, such as engineered cyanobacteria, from inexpensive renewable resources  
26 such as waste CO<sub>2</sub>. However, higher titer and rate of (*R*)-3HB production by cyanobacteria  
27 beyond that found in the current literature are critical for commercial applications. Herein, we  
28 employed a facile strategy to identify the rate-limiting step in photoautotrophic production of  
29 (*R*)-3HB by the cyanobacterium *Synechocystis* and found that acetoacetyl-CoA reductase  
30 activity is the bottleneck in the process. Optimization of the gene's ribosome binding site led to  
31 a 2.2-fold increase in enzyme activity. In the engineered organism, the (*R*)-3HB titer reached  
32 1.84 g L<sup>-1</sup> within 10 days, with peak productivity of 263 mg L<sup>-1</sup> day<sup>-1</sup>, using CO<sub>2</sub> and light as the  
33 sole carbon and energy sources. Moreover, dramatic changes in carbon partition were  
34 discovered in the (*R*)-3HB-producing cells along the course of cultivation using <sup>13</sup>C-metabolic  
35 flux analysis; after the rapid growth phase, a majority of carbon flux was redirected from the  
36 cell mass formation to the production of (*R*)-3HB in the engineered *Synechocystis* under the

37 examined experimental conditions.

38

## 39 Introduction

40 Conventional petroleum-derived plastics have become one of the most popular materials in  
41 modern society, with applications across domestic, medical and industrial domains. However,  
42 their various “single-use” or “short-life” applications and the concomitant plastic waste  
43 generated are causing escalating environmental problems due to their extremely slow  
44 degradation rates.<sup>1, 2</sup> Polyhydroxyalkanoates (PHAs) are biodegradable and biocompatible  
45 thermoplastics that show thermal and mechanical properties comparable to conventional  
46 plastics.<sup>1-3</sup> Therefore, PHAs have huge potential market in “short-life” applications, such as  
47 medical devices and food packaging.<sup>2, 4-8</sup> In nature, production of PHAs occurs in a variety of  
48 microorganisms as a means for carbon and energy storage under nutrient-unbalanced growth  
49 conditions.<sup>9</sup> Nevertheless, many efforts towards engineering microorganisms to synthesize  
50 PHAs in recent years demonstrate the difficulty in controlling the monomer composition (with  
51 several monomer of various carbon chain length), which is critical to the material functionality.<sup>2,</sup>  
52 <sup>4, 6, 10</sup> Additionally, since PHAs are macromolecules generated intracellularly, harvesting PHAs  
53 requires energy-intensive cell lysis.<sup>11</sup> One potential solution is to engineer organisms to produce  
54 PHA building-block molecules that can be excreted and then polymerized or co-polymerized at  
55 defined ratios to yield PHAs with the desirable thermal and mechanical properties.<sup>12-15</sup> (*R*)-3-  
56 Hydroxybutyrate (3HB), which is the most common building-block for PHAs,<sup>2, 4, 6, 8-10, 16, 17</sup> can  
57 potentially be used in various medical applications<sup>15</sup> and serve as a precursor for an array of  
58 stereo-specific, fine chemicals such as antibiotics, pheromones, and amino acids.<sup>12, 15</sup>

59 Chemical synthesis of chiral (*R*)-3HB utilizes a complex of 2,2'-bis(diphenylphosphino)-1,1'-

60 binaphthyl (BINAP)-coordinated Ruthenium (Ru) as a catalyst.<sup>18</sup> Ruthenium is one of the  
61 platinum group metals rarely found on earth, with world reserves estimated at only 5,000  
62 tons.<sup>19</sup> BINAP is a complex aromatic molecule and its synthesis and utilization also have  
63 negative environmental impact. In recent years, biotechnological synthesis of (*R*)-3HB has been  
64 proposed as an alternative to chemical synthesis,<sup>12</sup> and (*R*)-3HB production by genetically  
65 engineered *E. coli* has been reported.<sup>20-23</sup> However, biosynthesized (*R*)-3HB or PHAs are  
66 expensive owing to many factors, including consumption of glucose by *E. coli*, which contributes  
67 to 60% of the PHA cost.<sup>3</sup> The high cost of biologically produced PHAs not only limits their  
68 application to medical devices but also prohibits their broader applications in production of  
69 other disposable products such as food packaging. To address the cost issue, efforts have been  
70 made to convert waste organic carbon or CO<sub>2</sub> (instead of glucose) to PHAs.<sup>3, 24</sup> In particular,  
71 cyanobacterial production of PHAs has gained recent attention.<sup>16, 17</sup> Cyanobacteria are capable  
72 of using solar energy for CO<sub>2</sub> fixation, and are amenable to genetic manipulation.<sup>25-28</sup> Although  
73 photosynthetic production of (*R*)-3HB was demonstrated recently,<sup>29, 30</sup> the reported titers and  
74 productivities were relatively low, *e.g.*, 533 mg L<sup>-1</sup> and 25 mg L<sup>-1</sup> day<sup>-1</sup> by engineered  
75 *Synechocystis* sp. PCC 6803 (hereafter *Synechocystis*)<sup>29</sup> and 1.22 g L<sup>-1</sup> and 44 mg L<sup>-1</sup> day<sup>-1</sup> by  
76 engineered *Synechococcus elongatus* PCC 7942 (hereafter *S. elongatus*),<sup>30</sup> and improvements  
77 are needed to attain economic feasibility.

78 The goal of this study is to identify and mitigate the rate-limiting steps in (*R*)-3HB production  
79 in *Synechocystis*. We first designed and implemented a facile experiment to probe the kinetic  
80 bottleneck and the potential for photosynthetic (*R*)-3HB production in *Synechocystis*, and  
81 subsequently were able to mitigate the identified rate-limiting step via genetic engineering. The

82 dramatic changes in carbon partitioning in the engineered (*R*)-3HB-producing cells along the  
83 course of cultivation were also quantitatively delineated by <sup>13</sup>C-metabolic flux analysis. day-1

## 84 **Results and Discussion**

### 85 **A facile method to identify the bottleneck in cyanobacterial production of (*R*)-3HB**

86 A variety of chemicals are toxic to cyanobacteria, which limits their production by these  
87 organisms.<sup>31-33</sup> Thus, we first assessed the tolerance of *Synechocystis* to 3HB. Wild-type  
88 *Synechocystis* was cultivated in BG11 medium supplemented with (±)-3HB at concentrations of  
89 up to 50 g L<sup>-1</sup> inside a growth chamber containing 5% CO<sub>2</sub>. As shown in Figure S1, *Synechocystis*  
90 was able to grow at 3HB concentrations as high as 50 g L<sup>-1</sup>, though its growth rate was severely  
91 impaired at this level. Supplementation with 25 g L<sup>-1</sup> 3HB only slightly hampered cell growth,  
92 whereas 3HB supplemented at or below 10g L<sup>-1</sup> had no apparent effect on cell growth. Overall,  
93 our results indicate that 3HB at up to 25 g L<sup>-1</sup> has almost no toxicity to the growth of  
94 *Synechocystis*, which suggests that *Synechocystis* is a suitable host for photosynthetic  
95 production of these high levels of 3HB.

96 *In vivo*, the stereospecific (*R*)-3HB is biosynthesized from the central carbon metabolite,  
97 acetyl-CoA, two molecules of which are first condensed to form acetoacetyl-CoA in a reaction  
98 catalyzed by a thiolase (PhaA). Thereafter, acetoacetyl-CoA is reduced by acetoacetyl-CoA  
99 reductase (PhaB), the subsequently the coenzyme A group is removed, catalyzed by a  
100 thioesterase (TesB; Figure 1). Rational design and successful engineering efforts towards  
101 enhanced production of a compound, herein (*R*)-3HB, rely heavily on precise identification of

102 the rate-limiting steps.<sup>26, 34</sup> The traditional trial-and-error genetic engineering approach is time-  
103 consuming, given that the doubling time of *Synechocystis* is about 8 to 12 hours, which is much  
104 longer than that of *E. coli* (20 – 30 min). Kinetic flux profiling (KFP) is a powerful tool to identify  
105 bottlenecks in a biosynthetic pathway. Recently <sup>13</sup>C KFP was successfully applied to characterize  
106 the metabolic flux profiles of several recombinant cyanobacteria.<sup>35, 36</sup> Nevertheless, it might not  
107 have been effective in our case, due to the low abundance of the coenzyme A- associated  
108 intermediate compounds in the 3HB biosynthesis pathway and instrument's low sensitivity for  
109 detecting them.<sup>36</sup>

110 [Figure 1 to be inserted here]

111 To circumvent these issues, a facile method was designed to probe the metabolic bottleneck  
112 in cyanobacterial (*R*)-3HB production, the principle of which is depicted in Figure 2. It was  
113 demonstrated in previous studies that the TesB enzyme from *E. coli* exhibits relatively high  
114 activity towards the medium-chain-length acyl-CoAs over the two-carbon acetyl-CoA.<sup>29, 37</sup>  
115 Under photoautotrophic growth conditions, wild-type *Synechocystis* does not produce acetate,  
116 whereas heterologous expression of the *E. coli* TesB leads to acetate production and its  
117 excretion, likely owing to TesB's activity on acetyl-CoA (Figure 1).<sup>29, 37</sup> Thus, it would be  
118 expected that if TesB activity were the rate-limiting step, the (*R*)-3HB productivity would  
119 increase upon higher expression of TesB (Figure 2A, B). On the other hand, if PhaAB activities  
120 were the bottlenecks in (*R*)-3HB production, increased TesB activity would not affect  
121 production of (*R*)-3HB but would rather lead to an elevated ratio of acetate: (*R*)-3HB (Figure 2B,  
122 C). To this end, we devised a promoter library to tune the expression level of TesB in a *phaAB*-  
123 expressing *Synechocystis* strain. As shown in Figure 3, six natural and synthetic promoters,



124 including the *E. coli*  $\sigma^{70}$  promoter  $P_{tac}$ , the *Synechocystis* native promoter  $P_{psbA2}$  and four of their  
125 derivatives, were compared in expressing *TesB* in *Synechocystis*. The *rrnB* T1 terminator was  
126 added downstream from the *tesB* gene in all six constructs (Table 1), which apparently did not  
127 affect the production of (*R*)-3HB or acetate under the examined condition (Figure S2). The  $P_{tac}$   
128 promoter is a strong and near-constitutive promoter in *Synechocystis*.<sup>38</sup> The native  
129 *Synechocystis psbA2* promoter (hereafter  $P_{psbA12}$ ) is light inducible and its 5'-untranslated region  
130 (UTR) plays an important role in stabilizing the *psbA2* mRNA.<sup>39</sup> Therefore, the whole 5'-UTR or  
131 merely the ribosome binding site (RBS, including the Shine-Dalgarno [SD] sequence and the  
132 spacer sequence between the SD region and the start codon) of the  $P_{psbA12}$  was placed  
133 downstream of the  $P_{tac}$ , resulting in promoters  $P_{tac}$ -UTR or  $P_{tac}$ -SD. Because the AU-box in the 5'-  
134 UTR of  $P_{psbA12}$  was a negative element for gene expression,<sup>40</sup> it was deleted from the  $P_{psbA12}$   
135 promoter, leading to promoter  $P_{psbA14}$  (Figure 3). Moreover, promoters  $P_{psbA12}$  and  $P_{tac}$  were  
136 fused together to form the dual promoter,  $P_{psbA16}$ - $P_{tac}$ . The *TesB* expression cassettes were each  
137 inserted into the *Synechocystis* strain Abd which expresses *PhaAB* under the control of  $P_{tac}$   
138 promoter (Table 1), resulting in strains TTrK, SDTrK, UTRTrK, PTrK12, PTrK14 and PTrK16,  
139 respectively (Figure 3; Table 1).

140 [Figure 2 to be inserted here]

141 [Figure 3 to be inserted here]

142

143 When the engineered strains were grown under photoautotrophic conditions, the cultures  
144 reached the same cell densities in five days (Figure 4A). Strains TTrK and PTrK16 exhibited  
145 similar growth rate, (*R*)-3HB and acetate productivity, *tesB* transcript level and *TesB* enzyme

146 activity (Figure S3). However, the *tesB* transcript level in strain TTrK was much higher compared  
147 to all four other strains tested. The *tesB* transcript levels in strains SDTrK, UTRTrK, PTrK12 and  
148 PTrK14 were 33%, 56%, 46% and 40% of that in strain TTrK (Figure 4B). Since modification of  
149 the 5'-UTR was assumed to have little impact on gene transcription, the much lower *tesB*  
150 transcript levels in strains SDTrK and UTRTrK compared to that in strain TTrK might be  
151 attributed to the poor stability of the *tesB* mRNA product. The finding is consistent with a  
152 previous report that the RBS of the P<sub>psbA12</sub> promoter might be a target for the RNase E/G in  
153 *Synechocystis*.<sup>39,41</sup> Additionally, removing the AU-box, a possible target for the RNase E,<sup>40</sup> from  
154 P<sub>psbA12</sub> did not lead to a higher level of *tesB* transcript in *Synechocystis* strain PTrK14 (with  
155 promoter P<sub>psbA14</sub>) (Figure 4B).

156 [Figure 4 to be inserted here]

157  
158 We analyzed the (*R*)-3HB and acetate production levels in the same strains above and found  
159 that strain SDTrK produced the least amounts of (*R*)-3HB and acetate, 70.2 and 2.55 mg L<sup>-1</sup>,  
160 respectively (Figure 4C); the (*R*)-3HB titers for PTrk14, UTRTrK and PTrK12 were 141.3, 147.5,  
161 166.1 mg L<sup>-1</sup>, respectively, which were 2.0-2.4 times higher than that for SDTrK; the acetate  
162 titers reached 1.2-2.7 times that measured in SDTrK (Figure 4C). While the (*R*)-3HB titer for  
163 strain TTrK, 174.6 mg L<sup>-1</sup>, was only slightly higher than those for strains PTrk14, UTRTrK and  
164 PTrK12, the acetate titer produced by strain TTrK was over five-fold higher than all other strains  
165 (Figure 4C). The well-maintained cell growth rate (Figure 4A) and the excessively produced  
166 acetate by strain TTrK (Figure 4C) implied that supply of acetyl-CoA was sufficient and was  
167 probably upregulated for biosynthesis of (*R*)-3HB, as evidenced by a previous study.<sup>36</sup> The

168 scenarios depicted in Figure 4C-D were in line with our models, as illustrated in Figure 2. (*R*)-  
169 3HB biosynthesis in SDTrK represented limited TesB activity (Figure 2A); PTrk14, UTRTrK and  
170 PTrk12 represented matched PhaAB and TesB activities (Figure 2B); and TTrK stood for  
171 excessive TesB but limited PhaAB activities (Figure 2C). From another perspective, the ratio of  
172 acetate to (*R*)-3HB may serve as an indicator to probe an excess of the TesB activity: when TesB  
173 activity becomes excessive, the acetate to (*R*)-3HB ratio increases significantly (Figure 2, 5D).  
174 Overall, we were able to demonstrate that tuning down TesB activity by a factor of at least two  
175 had little impact on (*R*)-3HB production, whereas given high enough TesB activity (*i.e.*, in the  
176 case of TTrK), the PhaAB activity which converts acetyl-CoA to (*R*)-3HB-CoA became the  
177 bottleneck for (*R*)-3HB biosynthesis in *Synechocystis*.

178 In our previous study, the *in vitro* activity of thiolase PhaA was approximately 200-fold  
179 higher than that of the acetoacetyl-CoA reductase PhaB.<sup>29</sup> Therefore, we inferred that the  
180 activity of the acetoacetyl-CoA reductase (PhaB) was likely the bottleneck for (*R*)-3HB  
181 biosynthesis in strain TTrK.

## 182 **Optimization of the ribosome binding site for *phaB1***

183 Optimizing RBS is an efficient strategy for enhancing expression of a target gene in  
184 cyanobacteria.<sup>38, 42, 43</sup> Therefore, the RBS upstream of the *phaB1* gene was optimized to  
185 enhance the expression of acetoacetyl-CoA reductase for (*R*)-3HB biosynthesis in *Synechocystis*.  
186 It has been reported that the SD sequence UAAGGAGG, which is perfectly complementary to  
187 the 3'-terminal sequence of the 16S rRNA in the *Escherichia coli* K12 strain, enabled 3- to 6-fold  
188 higher translation efficiency than the SD sequence AAGGA, regardless of the spacing between

189 the SD sequence and the translation start codon – ATG.<sup>44</sup> In this study, the RBS upstream of the  
190 *phaB1* gene was examined, and it was found that the original SD sequence, 5'-AAGGAGTGG-3',  
191 did not perfectly complement the 3'-terminal sequence (5'-ACCUCCUUU-3') of the 16S rRNA in  
192 *Synechocystis*. The original RBS sequence, AAGGAGTGGAC, for *phaB1* was therefore replaced by  
193 sequence AAGGAGGTAAC (RBS<sub>opt</sub>) which was fully complementary to the 3'-terminal sequence  
194 of *Synechocystis* 16S rRNA (Figure 5A). The resultant strain was denominated strain R154 (Table  
195 1).

196 The acetoacetyl-CoA reductase (PhaB) activity in strain R154 was 2.2-fold higher than that in  
197 strain TTrK (Table 2; Figure 5B). While the growth of strain R154 was similar to that of strain  
198 TTrK under the examined culture condition (Figure 5C), strain R154 was able to produce (*R*)-3HB  
199 at a titer of 280.2 mg L<sup>-1</sup>, 1.6-fold higher than that of strain TTrK, after five days of  
200 photoautotrophic growth with NaHCO<sub>3</sub> as the sole carbon source (Figure 5D). Our results  
201 confirmed that PhaB activity was indeed the bottleneck for (*R*)-3HB production in *Synechocystis*,  
202 and they suggest that the new RBS, *i.e.*, RBS<sub>opt</sub>, is much more efficient in expressing the *phaB1*  
203 gene compared to the original RBS in our engineered *Synechocystis* strains.

204

205 [Figure 5 to be inserted here]

206

### 207 **Enhanced production of (*R*)-3HB from CO<sub>2</sub>**

208 Since the bottleneck of (*R*)-3HB biosynthesis in *Synechocystis*, the acetoacetyl-CoA reductase  
209 activity, has been mitigated (at least partially) in strain R154 (Figure 5), it would be interesting

210 to examine if this strain R154 shows higher photosynthetic productivity of (*R*)-3HB directly from  
211 CO<sub>2</sub> (rather than daily addition of bicarbonate) than the parental strain.<sup>29</sup> As shown in Figure 6A,  
212 strain R154 first showed a relatively fast “growth phase” during the first two days, and then cell  
213 growth slowed down in the “production phase”. (*R*)-3HB quickly accumulated in the production  
214 phase (Figure 6A), consistent with the previous observation that 3HB started to accumulate  
215 following the depletion of phosphate and the onset of slowed-down cell growth.<sup>29</sup> During the  
216 production phase (starting from day 2 until day 10), strain R154 continuously produced (*R*)-3HB  
217 at an average rate of 203 mg L<sup>-1</sup> day<sup>-1</sup> (Figure 6B). Notably, the volumetric productivity peaked  
218 on days 6~8, reaching 263 mg L<sup>-1</sup> day<sup>-1</sup> on day 7, and the highest specific productivity reached  
219 50 mg L<sup>-1</sup> day<sup>-1</sup> OD<sub>730</sub><sup>-1</sup> on day 2 and declined thereafter to 11.5 mg L<sup>-1</sup> day<sup>-1</sup> OD<sub>730</sub><sup>-1</sup> on day 10  
220 (Figure 6B). The (*R*)-3HB titer reached 1845 mg L<sup>-1</sup> at the end of the 10-day photoautotrophic  
221 cultivation period (Figure 6A). Compared to the literature,<sup>29</sup> the titer achieved in this study is  
222 3.5-fold higher and the average productivity is 7.3-fold higher than previously reported values.

223 To our knowledge, this result is, to date, the highest titer and productivity achieved in  
224 photoautotrophic production of 3-hydroxyalkanoic acids from CO<sub>2</sub>. The productivity is also  
225 higher than other compounds branching from the metabolic node of acetyl-CoA (Table S2).  
226 Without adding any organic carbon sources into the culture medium, the titer of the excreted  
227 (*R*)-3HB achieved in this study, equivalent to ~35% of the dry weight of the cells, has reached  
228 the same level as what was reported previously on cyanobacterial mixotrophic production of  
229 PHB that was biosynthesized as intracellular granules.<sup>45</sup> The demonstrated (*R*)-3HB productivity  
230 has therefore shed light on the potential capacity of engineered cyanobacteria in  
231 photoautotrophic production of acetyl-CoA-derived chemicals or biofuels using CO<sub>2</sub> as the only

232 carbon source.

233 [Figure 6 to be inserted here]

234

235 The dramatic increase of the (*R*)-3HB production rate compared to that in the previous study  
236 can probably be attributed to the following reasons. First, the bottleneck in the (*R*)-3HB  
237 biosynthesis pathway, *i.e.*, the relatively low enzyme activity of acetoacetyl-CoA reductase  
238 (encoded by *phaB*), was identified and subsequently alleviated by optimizing the RBS which  
239 increased the PhaB activity by 2.2-fold in strain R154 (Figure 5B; Table 2). Second, the culture in  
240 current study was aerated with 5% CO<sub>2</sub> instead of air, and the pH of the culture medium was  
241 stable at ~8.0 during the entire cultivation process, indicating that the CO<sub>2</sub> supply was sufficient.  
242 In contrast, in the previous study when the culture was aerated with ambient air (0.04% CO<sub>2</sub>),  
243 the pH of the culture medium reached 10~11,<sup>45</sup> which demonstrates that the CO<sub>2</sub> supply was  
244 limiting. Third, while in the previous study *Synechocystis* cells were cultivated by simply  
245 bubbling air into the flasks without shaking,<sup>45</sup> in this study the flasks containing *Synechocystis*  
246 cells were placed on a rotary shaker with a rotation rate of 150 rpm, which can improve CO<sub>2</sub>  
247 distribution and light delivery to the *Synechocystis* culture. It is noteworthy that the highest  
248 titer, 1.84 g L<sup>-1</sup>, of (*R*)-3HB achieved in this study is still far below the concentration of 3HB that  
249 *Synechocystis* can tolerate without a major decrease in growth rate, *i.e.*, 25 g L<sup>-1</sup> (Figure S1).  
250 Strategies to further increase the titer and productivity may include maximizing the PhaB  
251 activity via systematic optimization of the gene expression level,<sup>38</sup> and redirecting the central  
252 carbon flux towards (*R*)-3HB biosynthesis by blocking competing pathways, such as using the  
253 inhibitor cerulenin to limit the amount of acetyl-CoA channeling to fatty acid synthesis (Figure

254 1).<sup>46</sup>

255

### 256 **Metabolic fluxes redistribution in (*R*)-3HB-producing strain**

257 To better understand the physiology of the (*R*)-3HB-producing strain, we set up a <sup>13</sup>C-tracer  
258 experiment to profile the fluxome in strain R154 during different growth phases. We used a  
259 steady-state <sup>13</sup>C-flux strategy which is suitable for quantitative analysis of flux partitioning on  
260 metabolic branches.<sup>47</sup> The method can be applied to photomixotrophic growth of  
261 cyanobacteria.<sup>48</sup> We grew the R154 strain on fully labeled sodium bicarbonate (NaH<sup>13</sup>CO<sub>3</sub>) and  
262 unlabeled glucose, a mixture of isotopic carbon substrates that can be proportionally consumed  
263 by the cells, hence imprinting unique isotope patterns into the metabolic intermediates. When  
264 isotope pseudo-steady state was reached, we collected isotopomer information from  
265 proteinogenic amino acids for <sup>13</sup>C-based Metabolic Flux Analysis (MFA). Physiological data  
266 including cell growth and (*R*)-3HB production were also collected overtime.

267 Consistent with our observation of cultures grown under photoautotrophic conditions  
268 (Figure 6), R154 batch culture under photomixotrophic conditions showed a typical two-phase  
269 metabolism: the growth phase and the production phase (Figure S4). During the growth phase  
270 (day 1-2), R154 exhibited a specific growth rate of 0.049 and the excreted (*R*)-3HB was below  
271 the detection limit. Upon transition into the production phase (day 3-5), cell growth slowed  
272 down significantly and (*R*)-3HB accumulated in the medium (Figure S4). Figure 7 shows a  
273 snapshot of quantitative flux distribution during the production phase, and Figure 8 delineates  
274 the up- and down-regulation of the metabolic flux during the production phase when compared  
275 to that during the growth phase. The relative flux values, the exchange coefficients for

276 reversible reactions, and the 95% confidence intervals are shown in Supplementary file 2 and  
277 fitting results are shown in Figure S5. During the growth phase,  $^{13}\text{C}$ -MFA revealed highly active  
278 Calvin-Benson-Bassham (CBB) cycle, glycolytic pathway, C4 pathway and relatively moderate  
279 fluxes through the TCA cycle in R154. These results were comparable with the previous report  
280 on the fluxome in wild type *Synechocystis*,<sup>48</sup> reflecting a relatively stable architecture of  
281 *Synechocystis* metabolic network for light-driven growth. However, during the production  
282 phase, the fluxes were altered globally for the biosynthesis of (*R*)-3HB. Fluxes in the TCA cycle,  
283 photorespiration, and amino acid biosynthesis were 1000-fold lower, whereas the relative flux  
284 from 3PGA to (*R*)-3HB and part of the oxidative pentose phosphate (OPP) and CBB pathway was  
285 higher (Figure 8). Consequently, during the production phase, fluxes in pathways leading to  
286 intermediate compounds, *e.g.*, glyceraldehyde-3-phosphate (GAP) and amino acids (Figure 7),  
287 required for biomass formation were down significantly, while the flux from 3-  
288 phosphoglycerate (PGA) to acetyl-CoA and (*R*)-3HB production increased. This is consistent with  
289 our previous observation that the intracellular acetyl-CoA concentration was about two times  
290 higher in the production phase than that in the growth phase.<sup>29</sup>

291 [Figure 7 to be inserted here]

292 [Figure 8 to be inserted here]

293

294  $^{13}\text{C}$ -MFA results showed that 68.8% of the carbon input was redirected to (*R*)-3HB (51.3%)  
295 and the by-product acetate (17.5%) on day 4 (when cells were in the production phase) of the  
296 cultivation process. To our knowledge, this is the first report detailing that a cyanobacterium  
297 redistributes a majority of its carbon flux from biomass formation to the biosynthesis of



298 chemicals and fuels during different metabolic phases, which corroborates the remarkable  
299 flexibility of cyanobacterial carbon metabolism.<sup>26, 49</sup>

## 300 **Conclusions**

301 We first demonstrated that *Synechocystis* was able to tolerate as high as 50 g L<sup>-1</sup> of 3HB, with  
302 25 g L<sup>-1</sup> displaying minimal impact on cell growth, which implies that *Synechocystis* is a logical  
303 candidate to be engineered for high-level production of 3HB without compromising cell fitness.  
304 Subsequently, a facile method was employed to identify the bottleneck in biosynthesis of (*R*)-  
305 3HB in *Synechocystis*, which was found to be the enzyme activity of acetoacetyl-CoA reductase  
306 (PhaB). Through optimization of its gene's ribosome binding site, the acetoacetyl-CoA reductase  
307 activity was increased by 2.2-fold, leading to a dramatic increase in (*R*)-3HB production. The (*R*)-  
308 3HB titer reached 1845 mg L<sup>-1</sup> within 10 days, with a peak productivity of 263 mg L<sup>-1</sup> day<sup>-1</sup>, using  
309 CO<sub>2</sub> and light as the sole carbon and energy sources. The average (*R*)-3HB productivity of 184  
310 mg L<sup>-1</sup> day<sup>-1</sup> is four times higher than that of an engineered *S. elongatus* strain reported  
311 recently,<sup>29</sup> and it represents to date the highest yield and productivity of any phototrophically  
312 produced compound derived from acetyl-CoA (Table S2). <sup>13</sup>C-metabolic flux analysis  
313 quantitatively delineated the sequential two-phase metabolism profile in the (*R*)-3HB-  
314 producing cells. During the early growth phase, carbon fluxes primarily contribute to biomass  
315 formation, whereas when cells subsequently enter the production phase, the cyanobacterium  
316 redistributed most of carbon fluxes from biomass formation to the heterologous pathway, with  
317 68.8% carbon input redirected to (*R*)-3HB (51.3%) and acetate (17.5%) formation under the  
318 investigated experimental conditions. The significantly improved titer and rate in production of

319 (*R*)-3HB directly from CO<sub>2</sub> and sunlight, and the quantitative delineation of metabolic fluxes for  
320 cells along the course of cultivation should be seen as an important step in the potential  
321 commercialization of this technology for production of renewable (*R*)-3HB and PHAs.

322

## 323 **Materials and methods**

### 324 **Culture conditions**

325 All recombinant plasmids were constructed and stored using *E. coli* XL1-Blue MRF' (Stratagene,  
326 La Jolla, CA, USA) as the host strain. *Synechocystis* strains were grown in BG11 medium  
327 supplemented with 50 mM NaHCO<sub>3</sub> under a light intensity of 60 μE m<sup>-2</sup> s<sup>-1</sup> supplied by cool  
328 white fluorescent bulbs unless otherwise specified. For BG11-agar plates, 10 mM TES (pH 8.0), 3  
329 g L<sup>-1</sup> thiosulfate and 1.5% agar were supplemented into BG11 medium before autoclaving.

### 330 **Modification of *Synechocystis* genome**

331 The chromosome of *Synechocystis* strains was modified using methods described previously.<sup>38</sup>  
332 Basically, recombinant integration plasmids carrying the desired expression cassettes (Table 1)  
333 were constructed using pBluescript II SK(+) as the backbone. Each integration plasmid was then  
334 used to transform *Synechocystis* using a natural transformation protocol. Premethylation using  
335 the cytosine-specific methyltransferase, Slr0214, was used to treat the donor DNA prior to  
336 transforming *Synechocystis* whenever necessary.<sup>50</sup> The genotype of each engineered  
337 *Synechocystis* strain is described in Table 1. The genotypic purity of each strain was confirmed

338 by colony PCR.

### 339 **Production of (*R*)-3HB from bicarbonate**

340 *Synechocystis* strains were inoculated in 50-mL flasks containing 20 mL BG11 (10 mM TES-  
341 NaOH) to an initial OD<sub>730</sub> (optical density at 730 nm) of 0.1 and were grown in a shaking bed  
342 (150 rpm) at 30 °C with a light intensity of 60 μE m<sup>-2</sup> s<sup>-1</sup> until an OD<sub>730</sub> of ~1.5. Cells were then  
343 harvested by centrifugation and resuspended with 10 mL BG11 (10 mM TES-NaOH) contained in  
344 50-mL flasks to an initial OD<sub>730</sub> of 2.0. Then cells were incubated under the same culture  
345 condition for the following experiments unless otherwise specified. Every day, 0.05 mL cell  
346 culture was sampled for OD<sub>730</sub> measurements, before 0.5 mL 1.0 M NaHCO<sub>3</sub> was added to each  
347 culture. At that point, the pH was adjusted to ~8.0 with 10 N HCl. After 5 days of cultivation, the  
348 culture supernatant was collected after centrifugation and the (*R*)-3HB titers were analyzed by  
349 HPLC. All cultivation experiments were conducted at least in triplicate for each strain.

### 350 **Production of 3HB from carbon dioxide**

351 *Synechocystis* was inoculated into 50 mL autoclaved BG11 (10 mM TES-NaOH) medium  
352 contained in a 250-mL baffled flask with an initial OD<sub>730</sub> of 0.4. The culture was grown at 30 °C  
353 with continuous illumination of 100 μE m<sup>-2</sup> s<sup>-1</sup> for the first day and 300 μE m<sup>-2</sup> s<sup>-1</sup> for the rest of  
354 the experiment. The headspace of the culture flask was aerated with 5% (v/v) CO<sub>2</sub> (balanced  
355 with ambient air) at an aeration rate of 60 mL min<sup>-1</sup>. At the end of each day, 1 mL of culture was  
356 sampled and 1 mL 5x (5-fold concentrated) BG11 medium was added back into the culture until  
357 the end of day 3. After day 3, 1 mL of culture was sampled and 1 mL of 10x BG11 medium was

358 added back into the culture each day until the end of the experiment. Additionally, 0.33 mL  
359 sterilized deionized water was supplemented into the culture every day to compensate the  
360 water loss due to evaporation. The experiments were conducted in duplicate.

### 361 **Gene expression analysis by RT-qPCR**

362 Cells were resuspended to an initial OD<sub>730</sub> of 2.0 in BG11 (10 mM TES-NaOH) medium under  
363 continuous illumination of 60  $\mu\text{E m}^{-2} \text{s}^{-1}$ . Daily, 0.05 mL cell culture was sampled for analysis of  
364 the OD<sub>730</sub> before 0.5 mL 1.0 M NaHCO<sub>3</sub> was added to each culture and the pH was adjusted to  
365  $\sim 8.0$  with 10 N HCl. After 3.5 days of cultivation, approximately  $1.67 \times 10^8$  *Synechocystis* cells  
366 (assuming OD<sub>730</sub> of 0.6 equals to  $10^8$  cells mL<sup>-1</sup>)<sup>51</sup> were collected by centrifugation at 17,000g at  
367 4 °C for 1 min. The supernatant was discarded, and the cell pellet was directly used for RNA  
368 extraction using ZR Fungal/Bacterial RNA MiniPrep™ Kit (ZYMO Research, Irvine, CA, USA). The  
369 RNA was then quantified by RT-qPCR using methods described previously.<sup>29</sup> The primers used  
370 for RT-qPCR analysis are listed in Table S1.

### 371 **Enzyme activity assay**

372 *Synechocystis* cells were resuspended with an initial OD<sub>730</sub> of 2.0 in BG11 (10 mM TES-NaOH)  
373 supplemented with 50 mM NaHCO<sub>3</sub> and were grown under light of 60  $\mu\text{E m}^{-2} \text{s}^{-1}$  for 12 hours.  
374 Then,  $1.67 \times 10^9$  *Synechocystis* cells were collected by centrifugation at 8000g at 4 °C for 5 min.  
375 The supernatant was discarded, and the cell pellets were frozen on dry ice and stored at -80 °C  
376 before the assay. For the thioesterase enzyme activity assay, the cell pellet was resuspended  
377 with 500  $\mu\text{L}$  ice-cold 0.1 M Tris-HCl (pH 7.5) and lysed by sonication (100 cycles of 3-s-on/ 3-s-

378 off) in an ice-water bath. The cell lysate was centrifuged at 17000g at 4 °C for 10 min before the  
379 supernatant was analyzed for the thioesterase activity, following the previously established  
380 protocols but using butyryl-CoA as the substrate.<sup>29</sup> For the acetoacetyl-CoA reductase enzyme  
381 activity assay, the cell pellet was resuspended in 500  $\mu$ L ice-cold Buffer A [50 mM  $K_2HPO_4$ -HCl  
382 (pH 7.5), 10% glycerol, 1 mM EDTA, 1 mM DTT] supplemented with 0.1 mM PMSF, and was  
383 lysed by sonication (20 cycles of 3-s-on/ 3-s-off) in ice-water bath. The supernatant was  
384 analyzed for acetoacetyl-CoA reductase activity using the protocol established previously.<sup>29</sup>

### 385 **Product quantification**

386 The (*R*)-3HB and acetate concentrations were quantified by 1100 series HPLC (Agilent, Santa  
387 Clara, CA, USA) using the method described previously.<sup>29</sup> Briefly, samples of the *Synechocystis*  
388 culture were centrifuged at 17,000g for 1–2 min at room temperature and the supernatant was  
389 properly diluted before being analyzed on HPLC that was equipped with an Aminex HPX-87H  
390 anion-exchange column (Bio-Rad Laboratories, Hercules, CA) and a refractive index detector  
391 (Agilent, Santa Clara, CA, USA). The column temperature was maintained at 35 °C during  
392 operation. The mobile phase was 5 mM  $H_2SO_4$  and the flow rate was set as a linear gradient  
393 from 0.55 mL  $min^{-1}$  to 0.8 mL  $min^{-1}$  over 12 min, followed by an 8-min hold.

### 394 **<sup>13</sup>C-Metabolic flux analysis (MFA)**

395 Steady-state <sup>13</sup>C-MFA was adopted to quantify carbon fluxes through the central metabolic  
396 network in R154 strain. Cultures were illuminated at 60  $\mu E m^{-2} s^{-1}$  and grown on unlabeled  
397 glucose (10 mM) and  $NaH^{13}CO_3$  (60 mM). Cells were collected during the exponential growth

398 phase (day 2) and (*R*)-3HB production phase (day 4), respectively, and proteinogenic amino  
399 acids were analyzed by a GC-MS system including a 7890A GC system and a 5975C inert XL MSD  
400 with Triple-Axis Detector (Agilent, Santa Clara, CA, USA) using the same method as previously  
401 reported.<sup>52</sup> The central carbon network of *Synechocystis* was constructed based on collected  
402 genome knowledge, which has been supported by biochemical and isotope tracer  
403 experiments.<sup>48, 53-55</sup> The network includes the Calvin Benson Cycle, the EMP pathway, the C4  
404 pathway, the TCA Cycle, and photorespiration pathways (Figure 8; Supplementary File 3). The  
405 cell mass composition (Figure 8; Supplementary File 3) was based on a previous report.<sup>48, 56</sup> The  
406 (*R*)-3HB production pathway and the acetate byproduct pathway (owing to the low TesB  
407 activity towards acetyl-CoA) were lumped and included into the metabolic model. INCA, a  
408 recently developed <sup>13</sup>C-flux software based on the MATLAB platform<sup>57</sup> was utilized for flux  
409 estimation. The calculation of <sup>13</sup>C-metabolic flux was performed by minimizing the sum-of-  
410 squared residuals (SSR) between computationally simulated and experimentally determined  
411 measurements.

412

## 413 **Acknowledgements**

414 This study was supported in part by funding granted to Professor Deirdre R. Meldrum at  
415 Arizona State University for the support of the NEPTUNE project in the Center for Biosignatures  
416 Discovery Automation (B.W. and D.R.M). This work was authored in part by Alliance for  
417 Sustainable Energy, LLC, the manager and operator of the National Renewable Energy

418 Laboratory for the U.S. Department of Energy (DOE) under Contract No. DE-AC36-08GO28308.  
419 Funding provided by DOE Office of Energy Efficiency and Renewable Energy BioEnergy  
420 Technologies Office (B.W., J.Y., W.X. and P.C.M.). The authors are grateful to Dr. David R.  
421 Nielsen for valuable discussions and the help with HPLC. The  $^{13}\text{C}$ -flux software was kindly  
422 provided by Dr. Jamey D. Young at Vanderbilt University. The manuscript has been critically  
423 reviewed by Drs. Maria Ghirardi and Michael Seibert. The views expressed in the article do not  
424 necessarily represent the views of the DOE or the U.S. Government. The U.S. Government  
425 retains and the publisher, by accepting the article for publication, acknowledges that the U.S.  
426 Government retains a nonexclusive, paid-up, irrevocable, worldwide license to publish or  
427 reproduce the published form of this work, or allow others to do so, for U.S. Government  
428 purposes.

429

430

### 431 **Competing interests**

432 Part of this work has contributed to a patent application.

433

### 434 **Authors' Contributions:**

435 B.W. and D.R.M. conceived the study. B.W. and W.X. designed and carried out the experiments,  
436 analyzed the data, and drafted the manuscript. B.W., W.X., J.Y., P.C.M. and D.R.M. revised the  
437 manuscript. All authors read and approved the final manuscript.

438

439

440 **Table 1** Strains used in this study.

Strains	Genotype*	References
<i>E. coli</i>	$\Delta(mcrA)183 \Delta(mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1 recA1 gyrA96 relA1$	Stratagene
XL1-Blue MRF'	<i>lac</i> [ <i>F'</i> <i>proAB lac<sup>q</sup>ΔM15 Tn10</i> (Tet <sup>r</sup> )]	
<i>Synechocystis</i>		
SPA:ΔphaEC	$P_{tac}$ - <i>adhE2</i> (S2), Δ <i>phaEC</i> (S3)	29
ABd	$Cm^R$ - $P_{tac}$ - <i>phaA-phaB1</i> (S1), $P_{tac}$ - <i>adhE2</i> (S2), Δ <i>phaEC</i> (S3)	This study
TABd	$Cm^R$ - $P_{tac}$ - <i>phaA-phaB1</i> (S1), $P_{tac}$ - <i>tesB</i> -Kan <sup>R</sup> (S2), Δ <i>phaEC</i> (S3)	29
TTrK	$Cm^R$ - $P_{tac}$ - <i>phaA-phaB1</i> (S1), $P_{tac}$ - <i>tesB</i> -T1-Kan <sup>R</sup> (S2), Δ <i>phaEC</i> (S3)	This study
SDTrK	$Cm^R$ - $P_{tac}$ - <i>phaA-phaB1</i> (S1), $P_{tac}$ -SD- <i>tesB</i> -T1-Kan <sup>R</sup> (S2), Δ <i>phaEC</i> (S3)	This study
UTRTrK	$Cm^R$ - $P_{tac}$ - <i>phaA-phaB1</i> (S1), $P_{tac}$ -UTR- <i>tesB</i> -T1-Kan <sup>R</sup> (S2), Δ <i>phaEC</i> (S3)	This study
PTrK12	$Cm^R$ - $P_{tac}$ - <i>phaA-phaB1</i> (S1), $P_{psbA12}$ - <i>tesB</i> -T1-Kan <sup>R</sup> (S2), Δ <i>phaEC</i> (S3)	This study
PTrK14	$Cm^R$ - $P_{tac}$ - <i>phaA-phaB1</i> (S1), $P_{psbA14}$ - <i>tesB</i> -T1-Kan <sup>R</sup> (S2), Δ <i>phaEC</i> (S3)	This study
PTrK16	$Cm^R$ - $P_{tac}$ - <i>phaA-phaB1</i> (S1), $P_{psbA12}$ - $P_{tac}$ - <i>tesB</i> -T1-Kan <sup>R</sup> (S2), Δ <i>phaEC</i> (S3)	This study
R154	$Cm^R$ - $P_{tac}$ - <i>phaA</i> -(RBS <sub>opt</sub> )- <i>phaB1</i> (S1), $P_{psbA12}$ - $P_{tac}$ - <i>tesB</i> -T1-Kan <sup>R</sup> (S2), Δ <i>phaEC</i> (S3)	This study

441 \*S1, the insertion site on the chromosome of *Synechocystis* between *slr1495* and *sll1397*; S2, the insertion site  
 442 between *slr1362* and *sll1274*; S3, the insertion site between *slr1828* and *sll1736*.

443

444 **Table 2** Acetoacetyl-CoA reductase enzyme activities. \*

Strain	Expression cassette for acetoacetyl-CoA reductase	Enzyme activity
TTrK	$P_{tac}$ - <i>phaA-phaB1</i>	0.063 ± 0.013
R154	$P_{tac}$ - <i>phaA</i> -(RBS <sub>opt</sub> )- <i>phaB1</i>	0.139 ± 0.020

445 \* Enzyme activities were given in  $\mu\text{mol min}^{-1} \text{L}^{-1}$  cell extract.

446

447

448

449

450



451 **Figure captions:**

452 **Fig. 1** Photoautotrophic production of (*R*)-3HB and the byproduct acetate in *Synechocystis*.  
453 Abbreviations: PSI, Photosystem I; PSII, Photosystem II; Fatty acyl-ACP, fatty acyl-acyl carrier  
454 protein; PHB, poly-3-hydroxybutyrate; 3HB, 3-hydroxybutyrate; TCA, tricarboxylic acid; *phaA*,  
455 the gene encoding thiolase; *phaB*, the gene encoding acetoacetyl-CoA reductase; *tesB*, the gene  
456 encoding thioesterase.  
457

458 **Fig. 2** Schematic illustration of the method for identifying the bottleneck in (*R*)-3HB biosynthesis.  
459 Acetyl-CoA and (*R*)-3HB-CoA are competitive substrates for thioesterase TesB, so when the  
460 enzyme activity of TesB is excessive (*i.e.*, the activities of thiolase and acetoacetyl-CoA  
461 reductase are limiting) it would react extravagantly on acetyl-CoA, leading to higher amount of  
462 acetate relative to (*R*)-3HB. Abbreviations: Acetyl-CoA, acetyl-coenzyme A; 3HB, 3-  
463 hydroxybutyrate; PhaAB, thiolase and acetoacetyl-CoA reductase; TesB, thioesterase.  
464

465 **Fig. 3** Schematic structures of the constructs used to characterize a library of six promoters in  
466 *Synechocystis*. Each construct was integrated into the neutral site S2 (between *slr1362* and  
467 *sll1274*) of the chromosome of *Synechocystis* ABd [ $\text{Cm}^R$ - $P_{\text{tac}}$ -*phaA-phaB1*,  $P_{\text{tac}}$ -*adhE2*,  $\Delta$ *phaEC*],  
468 resulting in strains expressing *tesB* under the control of various promoters. Abbreviations: TSS,  
469 transcription start site; SD, Shine-Dalgarno sequence; *rrnB* T1, the T1 terminator downstream  
470 from the *rrnB* gene.  
471

472 **Fig. 4** Characterization of a library of five promoters in *tesB*-expressing *Synechocystis* strains. (A)  
473 Cell density of strains achieved after 5 days of photoautotrophic cultivation in BG11 medium  
474 with bicarbonate as the carbon source. (B) Abundance of *tesB* mRNA. (C) Titer of (*R*)-3HB (wide  
475 bar) and acetate (thin bar). (D) Acetate to (*R*)-3HB ratio in the culture medium.  
476

477 **Fig. 5** Optimization of the RBS for gene *phaB1* in *Synechocystis*. (A) The original and optimized  
478 ribosome binding sites. (B) Acetoacetyl-CoA reductase activity before (strain TTrK) and after  
479 (strain R154) RBS optimization; \*, given in  $\mu\text{mol min}^{-1} \text{L}^{-1}$  cell extract. (C) Cell growth curves for  
480 strains TTrK and R154 under the examined experimental conditions. (D) (*R*)-3HB titers from  
481 strains TTrK and R154.  
482

483 **Fig. 6** Photosynthetic production of (*R*)-3HB from CO<sub>2</sub> by engineered *Synechocystis* strain R154.  
484 (A) Time courses of cell growth and (*R*)-3HB production in the culture of *Synechocystis* strain  
485 R154. (B) Daily volumetric and specific (*R*)-3HB productivity of strain R154.  
486

487 **Fig. 7** Relatively quantitative flux distributions for (*R*)-3HB production in strain R154 on Day 4 (in  
488 the production phase). Arrow thickness is scaled proportionally to the flux values which are

489 relative to the CO<sub>2</sub> uptake rate. Abbreviations: G6P, Glucose 6-phosphate; Ru5P, Ribulose 5-  
 490 phosphate; RuBP, Ribulose biphosphate; F6P, fructose 6-phosphate; R5P, Ribose 5-phosphate;  
 491 FBP, Fructose biphosphate; X5P, Xylulose 5-phosphate; E4P, Erythrose 4-phosphate; DHAP,  
 492 Dihydroxyacetone phosphate; GAP, Glyceraldehyde-3-phosphate; SBP, Sedoheptulose  
 493 biphosphate; S7P, Sedoheptulose 7-phosphate; PGA, Phosphoglycerate; PEP,  
 494 Phosphoenolpyruvate; PYR, pyruvate; AcCoA, Acetyl Coenzyme A; CIT, Citrate; ICT, Isocitrate;  
 495 2OG, 2-oxoglutarate; SSA, Succinic semialdehyde; SUC, Succinate; FUM, Fumarate; MAL, Malate;  
 496 OAA, Oxaloacetate. Abbreviations for reactions: G6PD, Glucose 6-phosphate dehydrogenase;  
 497 PRK, Phosphoribulokinase; PGI, Phosphoglucose isomerase; TKT, Transketolase; PPI, Pentose  
 498 phosphate isomerase; PFK, Phosphofructosekinase; PPE, Phosphopentose epimerase; FBA,  
 499 Fructose biphosphate aldolase; TAL,transaldolase; SBA, Sedoheptulose biphosphate aldolase;  
 500 TPI, Triosephosphate isomerase; SBPS, Sedoheptulose biphosphatase; RBC, Ribulose  
 501 biphosphate carboxylase; GAPDH, Glyceraldehyde-3-phosphate dehydrogenase; ENO, Enolase;  
 502 PEPC, Phosphoenolpyruvate carboxylase; PK, pyruvate kinase; PDH, pyruvate dehydrogenase;  
 503 CS, citrate synthase; ME, malic enzyme; ACO, Aconitase; ICTDH, Isocitrate dehydrogenase;  
 504 OGDC, 2-oxoglutarate decarboxylase; SSADH, Succinic semialdehyde dehydrogenase; SDH,  
 505 Succinate dehydrogenase; FUS, Fumarase; MDH, Malate dehydrogenase.  
 506

507 **Fig. 8** Heatmap of relative flux fold changes between Growth Phase (Day 2) and Production  
 508 Phase (Day 4). Red color indicates up-regulation; green color indicates down-regulation; white  
 509 color indicates either no change of the reaction rate or the reaction rate was too low to be  
 510 considered and compared. Abbreviations: 2PGA, 2-phosphoglyceric acid; 2PG, 2-  
 511 phosphoglycolate; 3HB, 3-hydroxybutyrate; 3PGA, 3-phosphoglyceric acid; AC, acetate; ACA,  
 512 acetyl-CoA; AKG,  $\alpha$ -ketoglutarate; ALA, alanine; ARG, arginine; ASN, asparagine; CIT, citrate; CYS,  
 513 cysteine; DHAP, dihydroxyacetone phosphate; E4P,erythrose 4-phosphate; F6P, fructose 6-  
 514 phosphate; FBP, fructose-1,6-biphosphate; FUM, fumarate; G6P, glucose 6-phosphate; GA,  
 515 glycerate; GAP, glyceraldehyde 3-phosphate; GLC, glycolate; GLN, glutamine; GLX, glyoxylate;  
 516 GLY, glycine; GLU, glutamate; HIS, histidine; ICI, isocitrate; ILE, isoleucine; LEU, leucine; MAL,  
 517 malate; MTHF, 5,10-Methylenetetrahydrofolate (5,10-CH<sub>2</sub>-THF); OAA, oxaloacetate; PEP,  
 518 phosphoenolpyruvate; PHE, phenylalanine; PRO, proline; PYR, pyruvate; R5P, ribose 5-  
 519 phosphate; Ru5P, ribulose-5-phosphate; RuBP, ribulose-1,5-diphosphate; S7P, sedoheptulose-  
 520 7-phosphate; SBP, sedoheptulose-1,7-biphosphate; SER, serine; SUC, succinate; SucCoA,  
 521 succinyl-CoA; THR, threonine; TRP, tryptophan; VAL, valine; X5P, xylulose-5-phosphate.  
 522

### 523 **Table of contents entry (20 words)**

524 Mitigation of a bottleneck significantly improved (*R*)-3HB productivity, and metabolic flux  
 525 analysis delineated dramatic metabolic flux changes in cyanobacterium *Synechocystis*.  
 526

## 527 References

- 528 1. A. K. Singh, L. Sharma, N. Mallick and J. Mala, *J. Appl. Phycol.*, 2016, **29**, 1213–1232.
- 529 2. A. Anjum, M. Zuber, K. M. Zia, A. Noreen, M. N. Anjum and S. Tabasum, *Int. J. Biol. Macromol.*, 2016,  
530 **89**, 161–174.
- 531 3. Y. Wang, J. Yin and G. Q. Chen, *Curr. Opin. Biotechnol.*, 2014, **30**, 59–65.
- 532 4. Z. J. Li, K. Qiao, W. Shi, B. Pereira, H. Zhang, B. D. Olsen and G. Stephanopoulos, *Metab. Eng.*, 2016, **35**,  
533 1–8.
- 534 5. S. Y. Choi, S. J. Park, W. J. Kim, J. E. Yang, H. Lee, J. Shin and S. Y. Lee, *Nat. Biotechnol.*, 2016, **34**,  
535 435–440.
- 536 6. M. Yamada, K. Matsumoto, S. Uramoto, R. Motohashi, H. Abe and S. Taguchi, *J. Biotechnol.*, 2011, **154**,  
537 255–260.
- 538 7. H. Akiyama, H. Okuhata, T. Onizuka, S. Kanai, M. Hirano, S. Tanaka, K. Sasaki and H. Miyasaka,  
539 *Bioresour. Technol.*, 2011, **102**, 11039–11042.
- 540 8. G. Chen, in *Plastics from Bacteria*, ed. G. Chen, Springer, Berlin, Heidelberg, 2010, vol. 14.
- 541 9. R. A. J. Verlinden, D. J. Hill, M. A. Kenward, C. D. Williams and I. Radecka, *J. Appl. Microbiol.*, 2007,  
542 **102**, 1437–1449.
- 543 10. K. Ishida, Y. Wang and Y. Inoue, *Biomacromolecules*, 2001, **2**, 1285–1293.
- 544 11. J. Sheng, R. Vannela and B. Rittmann, *Bioresour. Technol.*, 2011, **102**, 1697–1703.
- 545 12. Y. Tokiwa and C. Ugwu, *J. Biotechnol.*, 2007, **132**, 264–272.
- 546 13. J. Adkins, S. Pugh, R. McKenna and D. R. Nielsen, *Front. Microbiol.*, 2012, **3**, 313.
- 547 14. G. Chen and Q. Wu, *Appl. Microbiol. Biotechnol.*, 2005, **67**, 592–599.
- 548 15. Q. Ren, K. Ruth, L. Thony-Meyer and M. Zinn, *Appl. Microbiol. Biotechnol.*, 2010, **87**, 41–52.
- 549 16. S. Zhang, Y. Liu and D. A. Bryant, *Metab. Eng.*, 2015, **32**, 174–183.
- 550 17. C. Troschl, K. Meixner and B. Drosch, *Bioengineering*, 2017, **4**, 26.
- 551 18. R. Noyori, T. Ohkuma, M. Kitamura, H. Takaya, N. Sayo, H. Kumobayashi and S. Akutagawa, *J. Am.*  
552 *Chem. Soc.*, 1987, **109**, 5856–5858.
- 553 19. J. Emsley, in *Nature's Building Blocks: an A-Z Guide to the Elements*, Oxford University Press, Oxford,  
554 England, UK, 2003, pp. 368–370.
- 555 20. H. Tseng, C. Martin, D. Nielsen and K. Prather, *Appl. Environ. Microbiol.*, 2009, **75**, 3137–3145.
- 556 21. H. J. Gao, Q. Wu and G. Q. Chen, *FEMS Microbiol. Lett.*, 2002, **213**, 59–65.
- 557 22. S. Y. Lee and Y. Lee, *Appl. Environ. Microbiol.*, 2003, **69**, 3421–3426.
- 558 23. Q. Liu, S. P. Ouyang, A. Chung, Q. Wu and G. Q. Chen, *Appl. Microbiol. Biotechnol.*, 2007, **76**, 811–818.
- 559 24. G. E. Luckachan and C. K. S. Pillai, *J. Polym. Environ.*, 2011, **19**, 637–676.
- 560 25. G. Luan and X. Lu, *Biotechnol. Adv.*, 2018, DOI: 10.1016/j.biotechadv.2018.01.005.
- 561 26. W. Xiong, M. Cano, B. Wang, D. Douchi and J. Yu, *Curr. Opin. Chem. Biol.*, 2017, **41**, 12–19.
- 562 27. C. J. Knoop, J. L. Ungerer, P. P. Wangikar and H. B. Pakrasi, *J. Biol. Chem.*, 2017, DOI:  
563 10.1074/jbc.R117.815886.
- 564 28. S. A. Angermayr, A. Gorchs Rovira and K. J. Hellingwerf, *Trends Biotechnol.*, 2015, **33**, 352–361.
- 565 29. B. Wang, S. Pugh, D. R. Nielsen, W. Zhang and D. R. Meldrum, *Metab. Eng.*, 2013, **16**, 68–77.
- 566 30. J. T. Ku and E. I. Lan, *Metab. Eng.*, 2018, **46**, 35–42.
- 567 31. R. L. Kitchener and A. M. Grunden, *Appl. Microbiol. Biotechnol.*, 2018, **102**, 1617–1628.
- 568 32. E. I. Lan, S. Y. Ro and J. C. Liao, *Energy Environ. Sci.*, 2013, **6**, 2672.
- 569 33. A. M. Ruffing and C. A. Trahan, *Algal Research*, 2014, **5**, 121–132.
- 570 34. C. J. Petzold, L. J. Chan, M. Nhan and P. D. Adams, *Front Bioeng Biotechnol*, 2015, **3**, 135.
- 571 35. X. Gao, F. Gao, D. Liu, H. Zhang, X. Nie and C. Yang, *Energy Environ. Sci.*, 2016, **9**, 1400–1411.
- 572 36. S. Noguchi, S. P. Putri, E. I. Lan, W. A. Lavina, Y. Dempo, T. Bamba, J. C. Liao and E. Fukusaki,  
573 *Metabolomics*, 2016, **12**, 26.
- 574 37. L. Nie, Y. Ren, A. Janakiraman, S. Smith and H. Schulz, *Biochemistry*, 2008, **47**, 9618–9626.
- 575 38. B. Wang, C. Eckert, P. C. Maness and J. Yu, *ACS Synth Biol*, 2018, **7**, 276–286.
- 576 39. I. Sakurai, D. Stazic, M. Eisenhut, E. Vuorio, C. Steglich, W. R. Hess and E. M. Aro, *Plant Physiol.*, 2012,  
577 **160**, 1000–1010.
- 578 40. G. K. Agrawal, H. Kato, M. Asayama and M. Shirai, *Nucleic Acids Res.*, 2001, **29**, 1835–1843.
- 579 41. Y. Horie, Y. Ito, M. Ono, N. Moriwaki, H. Kato, Y. Hamakubo, T. Amano, M. Wachi, M. Shirai and M.

- 580 Asayama, *Mol. Genet. Genomics*, 2007, **278**, 331–346.
- 581 42. E. Englund, F. Liang and P. Lindberg, *Sci. Rep.*, 2016, **6**, 36640.
- 582 43. A. L. Markley, M. B. Begemann, R. E. Clarke, G. C. Gordon and B. F. Pfleger, *ACS Synthetic Biology*,  
583 2015, **4**, 595–603.
- 584 44. S. C. Makrides, *Microbiol. Rev.*, 1996, **60**, 512–538.
- 585 45. B. Panda and N. Mallick, *Lett. Appl. Microbiol.*, 2007, **44**, 194–198.
- 586 46. J. Ni, F. Tao, Y. Wang, F. Yao and P. Xu, *Green Chem.*, 2016, **18**, 3537–3548.
- 587 47. N. Zamboni, S. M. Fendt, M. Ruhl and U. Sauer, *Nat. Protoc.*, 2009, **4**, 878–892.
- 588 48. L. You, B. Berla, L. He, H. B. Pakrasi and Y. J. Tang, *Biotechnol J*, 2014, **9**, 684–692.
- 589 49. N. Wan, D. M. DeLorenzo, L. He, L. You, C. M. Immethun, G. Wang, E. E. K. Baidoo, W. Hollinshead, J.  
590 D. Keasling, T. S. Moon and Y. J. Tang, *Biotechnol. Bioeng.*, 2017, **114**, 1593–1602.
- 591 50. B. Wang, J. Yu, W. Zhang and D. R. Meldrum, *Appl. Environ. Microbiol.*, 2015, **81**, 8500–8506.
- 592 51. X. Liu, J. Sheng and R. Curtiss, 3rd, *Proc. Natl. Acad. Sci. U. S. A.*, 2011, **108**, 6899–6904.
- 593 52. W. Xiong, L. Liu, C. Wu, C. Yang and Q. Wu, *Plant Physiol.*, 2010, **154**, 1001–1011.
- 594 53. S. Zhang and D. A. Bryant, *Science*, 2011, **334**, 1551–1553.
- 595 54. W. Xiong, T. C. Lee, S. Rommelfänger, E. Gjersing, M. Cano, P. C. Maness, M. Ghirardi and J. Yu, *Nat*  
596 *Plants*, 2015, **2**, 15187.
- 597 55. W. Xiong, D. Brune and W. F. Vermaas, *Mol. Microbiol.*, 2014, **93**, 786–796.
- 598 56. R. Saha, A. T. Verseput, B. M. Berla, T. J. Mueller, H. B. Pakrasi and C. D. Maranas, *PLoS One*, 2012, **7**,  
599 e48285.
- 600 57. J. D. Young, *Bioinformatics*, 2014, **30**, 1333–1335.
- 601